我們的科學顧問委員會 (SAB) 對我們的研發活動和策略提供外部科學審查。
MiRXES （覓瑞）SAB 由 覓瑞 聯合創始人和首席科學顧問 朱興奮教授主持。
• Associate Professor of Biochemistry, National University of Singapore
• Associate Professor of Chemical and Biomolecular Engineering, National University of Singapore
• Co-founder & Chief Scientific Advisor, MiRXES
• Shields Warren Mallinckrodt Professor of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center
• Director, Harvard Medical School Initiative for RNA Medicine at Beth Israel Deaconess Medical Center
• Co-discoverer of the second known microRNA and the first human microRNA
• Director, National University Cancer Institute, National University Health System
• Group Director of Research, National University Health System
• Deputy Director & Senior Principal Investigator, Cancer Science Institute, Singapore
• Vice Dean of Research & Provost’s Chair Professor, Yong Loo Lin School of Medicine, National University of Singapore
• Chief Medical Advisor, MiRXES
• Professor of Microbiology and Immunology, National University of Singapore
• Executive Director, Singapore Immunology Network, A*STAR
• Professor of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University
• Chief Scientific Officer, Theoria Science
• President, Japanese Society for Extracellular Vesicles
• Irene Tan Liang Kheng Professor in Medicine and Oncology, National University of Singapore
• Senior Consultant, Gastroenterology and Hepatology, National University Hospital
• Lead Principal Investigator, Singapore Gastric Cancer Consortium
• Chairman, National Colorectal Cancer Screening Committee, Health Promotion Board, Ministry of Health, Singapore.
• Chief Executive, National University Health System
• Senior Vice President (Health Affairs), National University of Singapore
• Leader, Single Cell Genomics Team, Spanish National Centre for Genomic Analysis (CNAG-CRG), Barcelona, Spain
• Scientific Co-founder, Omniscope
• Chairman of the Department of Clinical Oncology, The Chinese University of Hong Kong
• Li Shu Fan Professor of Clinical Oncology, The Chinese University of Hong Kong
• Past President, International Association for the Study of Lung Cancer (IASLC)
Zhou Lihan is the Co-founder and Chief Executive Officer of MiRXES. Lihan led MiRXES’ growth from a 3-man start-up in Singapore to a leader in RNA technology and disease early detection with operations globally.
Prior to founding MiRXES, Lihan led a research team at the Bioprocessing Technology Institute, A*STAR to develop a novel microRNA qPCR assay platform for biomarker and therapeutic target discovery. In 2015, Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35.
Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored and co-authored more than 20 peer-reviewed publications and several patent applications.
Zou Ruiyang is Co-founder and Chief Technology Officer of MiRXES. Ruiyang is responsible for MiRXES’s technology and diagnostic test development, and also oversees MiRXES’s China operations.
Prior to founding MiRXES, he was the Head of Bioinformatics at the MicroRNA Signature Identification Center, A*STAR. Ruiyang has a passion for science and is continuously innovating to discover technology that can be developed to practical applications that can be delivered to the public.
Ruiyang has a PhD in Chemical and Pharmaceutical Engineering from Singapore-MIT Alliance (NUS-MIT), Singapore. He also successfully completed his dual degree in 2007 where he attained Bachelor of Science, Molecular Science and Engineering, Nankai University, Tianjin, P. R. China, and Bachelor of Engineering, Molecular Science and Engineering, Tianjin University, Tianjin, P. R. China. Ruiyang has co-authored more than 10 publications and has eight patents and applications.
Isaac Ho is Chief Investment Officer of MiRXES where he oversees corporate development, investor relations as well as builds strategic partnerships with key healthcare players and financial institutions.
Prior to MiRXES, Isaac founded Singapore Health, and subsequently VentureCraft Group, a Singapore government accredited co-investment partner and incubator in the healthcare and biomedical sciences sector. He is a veteran in entrepreneurship, investment, and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Program for Biomedical Sciences.
Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).
Choo Beng Lor is the Chief Financial Officer of MiRXES and is responsible for matters relating to finance, internal controls, compliance, corporate management and investor relations.
He was previously with Zheneng Jinjiang Environment Holding Company Limited where he was the Financial Controller overseeing matters relating to financial management and reporting, compliance with post-listing obligations. Prior to that, Beng Lor spent 11 years being a CFO for companies including Cima NanoTech Pte Ltd, Sound Global Ltd and Sino Chemical Holdings Pte Ltd.
Beng Lor graduated with a Bachelor of Accountancy from Nanyang Technological University, Singapore. He is a Chartered Accountant of the Institute of Singapore Chartered Accountants.
Francine Wong is Assistant Vice President, Human Resource at MiRXES where she is responsible for developing and executing HR strategy in support of the business plan and strategic direction of the organization, in the areas of talent management, organizational development, performance & rewards, and learning & development.
She was previously the APAC Regional HR Director at A. Menarini Asia Pacific where she oversaw the HR function for 13 markets across the Asia Pacific region. Francine has diverse industry experience in logistics, engineering and banking, with bulk of her experience in healthcare, where she was the HR Leader, ASEAN at GE Healthcare and Director – Strategic HR Business Partner for Asia Growth Markets at ResMed. At ResMed, she was part of the Global HR Leadership Team and helped to grow the manufacturing hub fourfold and supported its expansion.
Francine graduated with a Bachelor of Business degree majoring in Human Resource Consulting from Nanyang Technological University and holds an MBA from the University of Manchester.
David Capes is Senior Vice President, Operations at MiRXES where he is responsible for the transformation of MiRXES into a global innovation enterprise.
David has over 31 years of extensive biomedical technology industry experience across all facets of general management and strategy, research and development, innovation, organic and inorganic opportunity identification and development, quality management, regulatory affairs management, manufacturing and sales. He was previously the Vice President for R&D for Greater Asia in Becton-Dickinson (BD) where he led the strategic innovation team and was instrumental in establishing the idea portfolio management for their new product development (NPD) portfolio. He was phenomenal in leading overachievement of the revenue target of innovation to NPD project approvals by five-fold. Prior to BD, he held senior management roles in Pathway Biomed and Rockeby Biomed.
David holds a Ph.D. in Pharmacy from Curtin University, and has authored and co-authored more than 54 publications and has two U.S. patents.
Teo Cher Hwa is the Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff at MiRXES. In his role as SVP, Health Innovation Delivery, Cher Hwa will help to embed MiRXES into the Singapore healthcare system through downstream market access efforts by driving adoption of MiRXES’s products.
Additionally as Chief of Staff, he will assist MiRXES’s Co-founder and CEO, Dr. Zhou Lihan in overseeing strategic initiatives from development to successful execution as well as working closely with functional heads in decision-making, program management & initiative implementation.
Cher Hwa has over 20 years of experience in grant funding, technology transfer, product development, and commercializing innovative technologies in telecommunications and biomedical devices. He was previously the Director of National Health Innovation Centre Singapore and was also their founding member. Prior to that, Cher Hwa was Vice President of the Communications & Healthcare Cluster at A*Star’s A*ccelerate Technologies where he oversaw technology transfer activities such as IP management, licensing, industry collaboration and translational funding projects in the MedTech and communications sectors.
Cher Hwa holds a Bachelor of Engineering (First Class Hons) in Electronic Engineering from the University of Sheffield and an MBA from the University of Manchester.
Dan Headon is the Senior Vice President (SVP), Marketing at MiRXES. In his role as SP, Marketing, Dan will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products.
Dan has more than 30 years of extensive experience in the biotechnology sector working for companies such as Biotech Australia, Millipore, Applied Biosystems and Illumina. Prior to joining MiRXES, he was the Director of Marketing for APAC at Illumina from 2008 to 2017, where he scaled the APAC marketing function from three to over 50 staff over a period of 10 years and contributed towards Illumina’s revenue growth in the region from USD 30 million per annum to over USD 500 million through a series of innovative marketing strategies
Dan holds a Bachelor of Science degree from Macquarie University and a Graduate Diploma of Marketing from Monash University.
Cheng He is Vice President, Research & Development at MiRXES where he leads research projects to discover and develop new microRNA biomarkers in tissues, cells and biofluids, as well as productize cell-free microRNA biomarkers into liquid biopsy assay.
Prior to this, Cheng He was a research scientist at Bioprocessing Technology Institute (BTI), A*STAR. Cheng He strives to solve healthcare problems with innovative technologies and has worked on multi-disciplinary fields including the development of nanowire sensors and mRNA clinical assay for cancer prognosis. He is flexible and adaptable with experience ranging from upstream R&D to downstream productization.
Cheng He holds a PhD in Electrical Engineering, National University of Singapore and a Masters in Material Science from MIT, as well as a Bachelor in Bioengineering from Nanyang Technological University.
Cheong Jit Kong is the Head of External Innovation at MiRXES and is responsible for the overall external R&D stakeholder engagement in key markets. He also supports MiRXES’ global clinical/scientific studies to generate scientific evidence and gather real-world clinical data. Additionally, Jit Kong serves concurrently as a Principal Investigator, Research Assistant Professor and Director of the NUS ncRNA Core Facility at NUS Yong Loo Lin School of Medicine.
Jit Kong is a recipient of multiple national and international research grants. He has extensive experience in signal transduction cascades in cancer biology, animal models of cancers, anti-cancer drug discovery as well as high-throughput miRNA expression screens.
Jit Kong graduated from a PhD program jointly administered by the National University of Singapore (NUS) and Harvard Medical School (HMS), Harvard University (U.S.A), where he was under the guidance of Professors Stephen Hsu I-Hong and Joseph Bonventre. He subsequently trained as a Singapore Millennium Foundation Postdoctoral Fellow at Prof David Virshup’s laboratory at Duke-NUS Medical School.
Zhao Pan is the Vice President, Genomics at MiRXES where she leads the overall strategy in MiRXES’s product and service pipelines as well as oversees the product lifecycle management.
Previously, Pan co-founded and was the Chief Commercial Officer of Lucence Diagnostics. Prior to this, she had experience in business development and field application in companies including Vishuo Biomedical and Vela Diagnostics. Pan believes in empowering physicians to improve patient outcome, and is an advocate for precision medicine, genetic testing and disease early detection.
Pan holds a PhD in Molecular and Microbiology from National University of Singapore Graduate School, and has recently obtained her Masters in Medical Genetics from Chinese University of Hong Kong (CUHK), Department of Obstetrics and Gynecology, Prince of Wales Hospital.
Tang Yew Chung is Vice President, Medical Affairs and Head of Early Detection at MiRXES where he oversees the strategic direction of clinician and researcher engagement and leads scientific and medical communications and partnerships. Yew Chung also heads our Japan market expansion and partnership efforts.
He has more than 10 years of experience in multi-disciplinary cancer research, including cancer genomics and systems biology, and has published 8 papers. Prior to joining MiRXES, Yew Chung spent nine years studying the functional genomics of breast cancer at Duke-NUS Medical School and was an Editor at Asian Scientist Magazine. He is constantly exploring innovative ways to communicate complex scientific information to the mass audience in a non-technical and engaging way.
Yew Chung has a PhD and MSc in Molecular Engineering of Biological and Chemical Systems from the Singapore-MIT Alliance, and a BEng in Chemical Engineering (Specializing in Biopharmaceutical Engineering) from the National University of Singapore.
Jeremiah Decosta is Vice President, Operations at MiRXES, where he leads the manufacturing strategy and oversees the management of quality control, quality assurance, supply chain and regulatory affairs.
Prior to this, Jeremiah served as the Production Director at APTA Biosciences, and was also Head of Operations at Vela Diagnostics. He has worked in MNCs and start-ups, and is both a leader and team player with management and hands-on experience.
Jeremiah holds a bachelor’s degree in Biomedical Science from the University of Bradford, UK.
Zhou Qiumei is the Vice President, Manufacturing & Regulatory Affairs at MiRXES China. Qiumei oversees the overall manufacturing and production capabilities, as well as manages the regulatory affairs, quality control and quality assurance in MiRXES China.
She has management experience of more than 10 years having held positions in various biotechnology and medical device companies such as Anrei Medical Holding Company, Hangzhou Singclean Medical Products Co. Ltd., Hangzhou Medzone Biotech Company and Hangzhou NeuroPeptide Biological Science and Technology Incorporation Ltd. Qiumei is well-versed in the construction of Good Manufacturing Practices certified facility, establishment of quality management system, production process of medical devices, as well as familiar with the laws and regulations regarding medical devices and in-vitro diagnostic products in both China and Europe.
Qiumei holds a Master of Science in Biochemistry and Molecular Biology from Zhejiang Sci-Tech University.
Larbi Gallagher is Vice President, Strategy and Growth Operations at MiRXES and oversees MiRXES’s U.S. business development operations.
Larbi has over 16 years of global cross-commercial leadership experience in biotech/life sciences where he worked in established companies including Illumina, Thermo Fisher Scientific Inc and Djinndustries in the U.S., China, Japan and Australia. Of the 16 years, he spent 10 years managing international teams in Asia Pacific. Larbi has a clear history of efficiency with organizational design and business execution, as well as a strong reputation for ethical behavior in China and respect and collaboration while in Japan. He is committed to helping his teams make breakthroughs in their projects or removing obstacles to their success.
Larbi holds a Master of Science in Plant Molecular & Cellular Biology, University of Florida, and a Bachelor of Science in Environmental Horticulture, University of Florida.
Ray Ong is the Vice President,Commercial and Head of Precision Oncology & Pandemic Response at MiRXES where he drives the overall strategy for business development and sales of MiRXES’s products and services.
Before joining MiRXES, Ray was the Oncology Business Development Manager at ThermoFisher Scientific, India Pacific, where he supported the Clinical Sequencing Division efforts in the Oncology Segment with active engagement with pharma, testing labs and key oncologists. In 2019, he collaborated with the local lung cancer network to successfully establish a multiple pharma co-payment model for lung cancer patients in Malaysia. Ray has previously served as a product manager with Bio-Rad Laboratories and was involved in its entry into the molecular diagnostics space with EGFR T790M testing for Osimertinib.
Ray has a PhD in Neurobiology under the Department of Physiology with the School of Medicine at National University of Singapore.
Guy Afseth is Head, Business Development at MiRXES USA. Guy is responsible for establishing key partnerships with leaders in biopharmaceutical, molecular diagnostics and academic institutions and supporting the incorporation of MiXRES technology into miRNA-based assay development of molecular diagnostics offering high value for patient care.
He has spent over 25 years in the Life Sciences and Molecular Diagnostics industries in technical, sales, product management and business development roles. Prior to MiRXES, Guy has held positions in business development, portfolio and product management and marketing in companies including Codex DNA, Roche Molecular Solutions, Gilson Inc., Thermo Fisher Scientific and Abbott Molecular. He is a passionate, customer-focused leader in life sciences and molecular diagnostics industries with broad technical and commercial abilities, and institutional knowledge gained from dominant diagnostic players.
Guy has a Master of Arts in Marketing Management from DePaul University, Chicago, Illinois and a Master of Science in Molecular Microbiology from Washington State University, Pullman, Washington.
Yoong Li-Foong is the Representative Director and Country Manager of MiRXES Japan. Li-Foong led the setting up of MiRXES subsidiary in Tokyo, Japan, where she now heads the business development and market expansion, as well as overseeing the overall operations.
She has more than 13 years of research experience in USA and Japan, including genetics, development biology and cellular signaling, and has published eight papers. Prior to joining MiRXES, Li-Foong has accumulated more than 10 years of research experience in Japan’s largest national research institute, RIKEN, where she has also received the prestigious international fellowship award from Human Frontier Science Program. She is passionate about bringing MiRXES’s innovative disease early detection solutions, from lab to user, so that more people can be benefited from a better and earlier diagnosis.
Li-Foong has a PhD in Biochemistry from the National University of Singapore.
周礪寒是覓瑞的聯合創始人兼執行總裁。覓瑞在礪寒的領導下，從新加坡一家三人的起步公司成長為 RNA 技術和疾病早期檢測的前鋒，業務遍及全球。在成立覓瑞前，礪寒 領導 A*STAR 生物加工技術研究所的一個研究團隊，開發了一種用於生物標誌物和探索治療靶標的新型 microRNA qPCR 檢測平台。2015 年，Lihan 被《麻省理工科技評論》評為 “35 歲以下創新人士”中的一員。礪寒在新加坡國立大學 楊潞齡醫學院獲得生物化學博士學位。礪寒 撰寫和合著了20多篇同行評議論文和若干專利申請。
鄒瑞陽 是覓瑞的聯合創始人兼首席技術官。瑞陽 負責 MiRXES 的技術和診斷測試開發，也監督 覓瑞 在中國的運營。在成立 覓瑞 前，他是 A*STAR MicroRNA 標記物鑑定中心的生物資訊部負責人。瑞陽 對科學充滿激情，並不懈進行創新，以發掘能夠轉化為可用於公眾的實用性技術。Ruiyang 擁有新加坡-MIT 聯盟（NUS-MIT，新加坡）的化學和製藥工程學博士學位。他還於 2007 年成功修完雙學位，獲得中國天津南開大學分子科學與工程理學學士學位，以及中國天津市天津大學分子科學與工程學學院工程學士學位。Ruiyang 已合著 10 余篇論文，擁有 8 項專利和專利申請。
Isaac Ho 是覓瑞 的首席投資官，他負責監督企業發展、投資者關係，以及跟關鍵醫療保健翹楚和金融機構建立戰略夥伴關係。Isaac 在加入 覓瑞 前創立了 Singapore Health，隨後創辦的 VentureCraft Group是新加坡政府認證的醫療保健和生物醫學科學領域的共同投資夥伴和孵化機構。他是一位在創業、投資和企業管理方面的斫輪老手。在他的領導下，Venturecraft Group 被任命為SPRING Singapore 生物醫學科學行業特定加速器計劃中的助推公司。Isaac 畢業於迪肯大學，擁有商業（營銷管理）學士學位。
Choo Beng Lor 是覓瑞 的首席財務官，負責有關財務、內部控制、秉守規則、公司管理和投資者關係等事務。他曾就職於浙能錦江環境控股有限公司，任財務總監，負責監督有關財務管理、報告和上市後履行承諾等事項。此前，Beng Lor 曾投入11 年，在 Cima NanoTech Pte Ltd、Sound Global Ltd 和 Sino Chemical Holdings Pte Ltd 等公司擔任 首席財務官。Beng Lor 畢業於新加坡南洋理工大學，獲得會計學士學位。他是新加坡特許會計師協會的特許會計師。
Francine Wong 是覓瑞人力資源部總監，負責制定和執行人力資源戰略，為公司的經營計劃和戰略方向提供支持，以輔佐公司在人才管理、機構發展、績效和獎勵，以及學習和發展方面的企業計劃和發展方向。之前她是 A. Menarini Asia Pacific 的亞太地區區域人力資源總監，主管亞太地區 13 個市場的人力資源職能。Francine 在物流、工程和銀行等方面擁有多元的行業經驗，其大部分經驗側重於醫療保健，因她曾在 GE Healthcare 擔任其東盟地區的人力資源負責人，並在瑞思邁公司擔任亞洲增長市場戰略人力資源業務合作夥伴總監。在瑞思邁，她是其全球 HR 領導團隊中的一員，幫助製造中心增長了四倍，並輔佐其擴張。Francine 畢業於南洋理工大學，在人力資源諮詢專業獲得商業學士學位，並擁有曼徹斯特大學 MBA 學位。
David Capes 是覓瑞創新部全球負責人，他負責將覓瑞轉化為全球創新企業。David 擁有超過 31 年廣博的生物醫學技術產業經驗，橫跨一般性管理和戰略、研發、創新、自生和刻意機會識別和開發、質量管理、法規事務管理、製造和銷售等方方面面。他之前曾是 Becton-Dickinson (BD) 大亞洲區研發副總裁，領導戰略創新團隊，並在建立新產品開發 (NPD) 組合的理念組合管理上發揮了重要作用。在他的帶領下，從創新變爲獲批新產品開發項目的收入超額提高了五倍，表現非凡。在加入 BD 前，他在 Pathway Biomed 和 Rockeby Biomed 擔任高級管理職務。David 擁有科廷大學藥學博士學位，曾撰寫和合著超過 54 篇論文，擁有兩項美國專利。
Teo Cher Hwa 是 覓瑞健康創新交付部高級副總裁 (SVP) 和縂謀略官。在其健康創新交付高級副總裁的崗位上，Cher Hwa 推動采用覓瑞產品，全力為其開路進入下遊市場，幫助將覓瑞 嵌入新加坡醫療保健系統。此外，作為縂謀略官，他協助覓瑞的聯合創始人和行政總裁周礪寒博士從策謀以至成功執行戰略點子，並在決策、項目管理和點子落實方面與各職能部門的負責人密切合作。Cher Hwa 在融資、技術轉讓、產品開發和電信及生物醫學設備創新技術商業化方面擁有 20 餘年經驗。他之前曾擔任新加坡國家健康創新中心總監，也是該中心的創始成員。此前，Cher Hwa 曾擔任 A*Star’s A*ccelerate Technologies 通信和醫療事業群副總裁，負責監督醫療技術和通信部門的技術轉讓活動，如知識產權管理、許可、行業合作和轉化性融資項目。Cher Hwa 擁有謝菲爾德大學電子工程學士學位（一等榮譽）和曼徹斯特大學 MBA 學位。
Cheng He 是覓瑞研發部副總裁，他在該部門領導研究項目，以發現和開發組織、細胞和生物體液中新的 microRNA 生物標誌物，以及將無細胞 microRNA 生物標誌物產品化以用於液體活檢檢測。此前，Cheng He是 A*STAR 生物加工技術研究所 (BTI) 的研究員。Cheng He 致力於用創新技術解決醫療問題，曾在多個跨學科領域工作，包括開發納米線傳感器的開發和癌症預後 mRNA 臨床檢測。他處事靈活，適應性極強，擁有從上游研發以至下游產品化方面的經驗。Cheng He 擁有新加坡國立大學電氣工程博士學位、麻省理工學院材料科學碩士學位，以及南洋理工大學生物工程學士學位。
Cheong Jit Kong 是覓瑞 外部創新的主管，負責外部研發利益相關者整體參與關鍵市場的事宜。他還輔佐覓瑞的全球臨床/科學研究，以產出科學證據並收集實際臨床數據。此外，Jit Kong 同時在新加坡國立大學楊潞齡醫學院擔任主要研究者、研究助理教授和該醫學院新加坡國立大學 ncRNA 核心機構 負責人。Jit Kong 是多個國家和國際研究補助金的獲得者。他在癌症生物學的信號轉導級聯、癌症動物模型、抗癌藥物發現以及高通量 miRNA 表達篩選方面具有豐富的經驗。Jit Kong畢業於新加坡國立大學 (NUS) 和哈佛大學 (U.S.a) 哈佛醫學院 (HMS) 合辦的博士項目，其導師為 Stephen Kong Hsu I-Hong 和 Joseph Bonventre 教授。他隨後在在杜克大學-新加坡國立大學醫學院的 David Virshup 教授實驗室接受新加坡千禧基金會博士後培訓。
Zhao Pan 是覓瑞的產品副總裁，她領導 MiRXES 產品和服務管道的總體策略，並監督產品生命周期的管理工作。此前，Pan 是 Lucence Diagnostics 的共同創始人，並曾擔任其首席商務官。而在這之前，她在多家公司經驗過業務開發和現場應用，包括Vishuo Biomedical 和 Vela Diagnostics。Pan 相信要賦予醫生能力改善患者的醫療結果，她是精準醫療、基因檢測和疾病早期檢測的倡導者。Pan 擁有新加坡國立大學研究生院分子與微生物學博士學位，近日獲得了威爾斯親王醫院婦產科香港中文大學 (CUHK) 醫學遺傳學碩士學位。
Tang Yew Chung 是覓瑞科學和醫學事務部副總裁助理，負責臨床醫生和研究者參與的戰略方向，並領導科學和醫學的交流以及合作夥伴關係。Yew Chung 也負責在日本擴展市場與進行合作的工作。他擁有超過 10 年多學科癌症研究的經驗，包括癌症基因組學和系統生物學，已發表八篇論文。Yew Chung 在加入覓瑞前，在杜克大學-新加坡國立大學醫學院花了九年時間研究乳腺癌的功能基因組學，也是《亞洲科學家》雜誌的編輯。他不斷地探索新穎途徑，以非技術性的有趣方式向廣大受眾宣傳複雜的科學資訊。Yew Chung 擁有新加坡-MIT 聯盟的生物和化學系統分子工程博士學位和碩士學位，以及新加坡國立大學化學工程 （生物製藥工程專業）學位。
Jeremiah Decosta 是覓瑞 生產和法規事務部副總裁，他負責領導生產策略並主管質量控制、質量保證、供應鏈和法規事務。此前，Jeremiah 在 APTA Biosciences 擔任生產總監，也是 Vela Diagnostics 的運營負責人。他曾在多家跨國企業與起步公司工作，既是領導者，又有團隊精神，擁有管理和實際經驗。Jeremiah 擁有英國布拉德福德大學生物醫學科學學士學位。
Zhou Qiumei 是覓瑞中國區製造和法規事務部副總裁。Qiumei 負責監督覓瑞中國區的整體製造和生產能力，以及管理法規事務、質量控制和質量保證。她曾在安瑞醫療控股公司、杭州協合醫療用品有限公司、杭州銘眾生物技術公司、杭州紐龍生物科技有限公司等各家生物技術和醫療器械公司任職，具有超過 10 年的管理經驗。Qiumei 精通醫療器械生產質量管理規範認證設施的建設、質量管理體系的建立、醫療器械的生產流程，並熟悉中國和歐洲有關醫療器械和體外診斷產品相關的法律法規。Qiumei 持有浙江科技大學生物化學與分子生物學碩士學位。
Larbi Gallagher 是覓瑞戰略和增長運營部副總裁，監督 MiRXES 在美國的業務開發運營。Larbi 在生物科技/生命科學領域擁有超過 16 年的全球跨商業領導經驗，曾在位於美國、中國、日本和澳大利亞的知名公司工作 ，包括Illumina、Thermo Fisher Scientific Inc 和 Djinndustries。在此 16 年裏，他有 10 年時間在亞太地區管理國際團隊。Larbi 在組織設計和業務執行上歷來的效率清晰可見，其在中國的誠信操守和在日本的莊敬與協作精神都備受讚譽。他致力於幫助他的團隊在他們的項目中取得突破，或幫他們消除障礙，以取得成功。Larbi 擁有佛羅里達大學植物分子和細胞生物學科學碩士學位，以及佛羅里達大學環境園藝科學學士學位。
Ray Ong是覓瑞商業運營部副總裁，推動覓瑞 產品和服務部業務開發和銷售的總體策略。Ray 在加入覓瑞 前，是 ThermoFisher Scientific印度太平洋地區的腫瘤學業務開發經理，通過與製藥、檢測實驗室及主要腫瘤學家進行積極合作，輔佐臨床測序部門在腫瘤學部分的工作。2019 年，他與馬來西亞肺癌網絡合作，成功地為此國的肺癌患者建立了多家製藥公司共同支付模式。Ray 之前曾擔任 Bio-Rad Laboratories 的產品經理，參與了其憑EGFR T790M 檢測Osimertinib進軍分子診斷空間的工作。Ray 在新加坡國立大學醫學院生理學系擁有神經生物學博士學位。
Guy Afseth 是覓瑞美國業務開發部負責人。Guy 負責與生物製藥、分子診斷和學術機構的標杆人物建立關鍵的夥伴關係，並輔佐將覓瑞 技術納入依據miRNA 分子作診斷分析的研發，以為患者護理提供高值服務。他在生命科學和分子診斷行業從事技術、銷售、產品管理和業務開發投入了超過 25 年。Guy 在加入覓瑞前，曾在包括 Codex DNA、Roche Molecular Solutions、Gilson Inc.、Thermo Fisher Scientific 和 Abbott Molecular 在內的公司擔任業務開發、產品組合和產品管理及營銷的崗位。他投身於生命科學和分子診斷行業，是一位充滿激情並以客戶為中心的領導者，具有廣博的技術和商業能力，並從執牛耳的診斷機構處獲得機構知識。Guy 擁有伊利諾伊州芝加哥德保羅大學的營銷管理碩士學位，以及華盛頓普爾曼州立大學的分子微生物學科學碩士學位。
Yoong Li-Foong 是覓瑞日本國經理助理和代表董事。Li-Foong 領導覓瑞子公司在日本東京成立，她現在負責業務發展和市場拓展，並監督整體運營。她在美國和日本擁有超過 13 年的研究經驗，包括遺傳學、發育生物學和細胞信號，並發表了八篇論文。在加入覓瑞前，Li-Foong 已經在日本最大的國家研究所理化學研究所積累了超過 10 年的研究經驗，在那裏她還獲得了人類前沿科學計劃榮耀的國際研究員獎學金。她熱衷於將覓瑞創新的疾病早期檢測解決方案從實驗室帶給用戶，讓更多人能夠從更好和更早的診斷中獲益。Li-Foong 擁有新加坡國立大學生物化學博士學位。